4D Molecular Therapeutics granted 96,000 RSUs to new employees to attract talent as part of its employment award plan.
Quiver AI Summary
4D Molecular Therapeutics, a late-stage biotechnology firm, announced the granting of 96,000 Restricted Stock Units (RSUs) to seven new non-executive employees as part of its 2025 Employment Inducement Award Plan. This grant aims to attract new talent to the company, which specializes in developing targeted therapeutics for various diseases. 4DMT's lead product, 4D-150, aims to revolutionize the treatment of blinding retinal vascular diseases by offering sustained delivery of anti-VEGF biologics through a single injection, currently in Phase 3 trials for wet age-related macular degeneration and diabetic macular edema. Additionally, the company is developing 4D-710, a genetic medicine for cystic fibrosis. All product candidates are still in clinical or preclinical stages and have not yet received regulatory approval.
Potential Positives
- Granting of 96,000 Restricted Stock Units (RSUs) to new employees indicates strong commitment to attracting talent, which can enhance the company’s capabilities and innovation.
- 4D-150 is positioned as a foundation therapy for treating blinding retinal vascular diseases, showing potential to transform treatment paradigms and reduce patient treatment burdens with its multi-year delivery system.
- Advancement of 4D-150 into Phase 3 development underscores the potential for significant market opportunities in treating wet age-related macular degeneration and diabetic macular edema.
- 4D-710 represents a breakthrough as the first genetic medicine for cystic fibrosis with a successful delivery method, highlighting the company's innovative approach to addressing complex diseases.
Potential Negatives
- The press release highlights that all of the company's product candidates are still in clinical or preclinical development, indicating that they have not yet achieved regulatory approval, which may raise concerns about the company's viability and future revenue generation.
- The statement that no representation is made regarding the safety or effectiveness of the company's product candidates may undermine investor confidence and highlight the risks associated with investing in the company.
- The granting of a substantial number of Restricted Stock Units (RSUs) to new employees may raise questions about the company's financial health and the need to incentivize talent amidst uncertainty regarding product approvals and commercialization timelines.
FAQ
What recent stock grants were announced by 4D Molecular Therapeutics?
On September 8, 2026, 4DMT granted seven non-executive employees 96,000 Restricted Stock Units (RSUs).
What is the purpose of the RSUs granted by 4DMT?
The RSUs were granted to induce new employees to join the company under the 2025 Employment Inducement Award Plan.
What are the main product candidates of 4D Molecular Therapeutics?
4DMT's lead product candidate is 4D-150, aimed at treating retinal vascular diseases, and 4D-710 for cystic fibrosis.
Which diseases is 4D-150 targeting?
4D-150 targets wet age-related macular degeneration and diabetic macular edema.
Are 4DMT's product candidates approved for marketing?
No, all of 4DMT's product candidates are still in clinical or preclinical development and not FDA approved.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FDMT Insider Trading Activity
$FDMT insiders have traded $FDMT stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $FDMT stock by insiders over the last 6 months:
- DAVID KIRN (See Remarks) has made 0 purchases and 9 sales selling 283,334 shares for an estimated $3,445,111.
- SCOTT BIZILY (Chief Legal Officer) has made 0 purchases and 4 sales selling 13,664 shares for an estimated $165,463.
- ASHOO GUPTA (VP, Finance and Controller) has made 0 purchases and 2 sales selling 390 shares for an estimated $3,357.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$FDMT Hedge Fund Activity
We have seen 88 institutional investors add shares of $FDMT stock to their portfolio, and 82 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 2,511,887 shares (+inf%) to their portfolio in Q2 2026, for an estimated $33,408,097
- TRAILS EDGE CAPITAL PARTNERS, LP added 2,227,917 shares (+inf%) to their portfolio in Q2 2026, for an estimated $29,631,296
- POINT72 ASSET MANAGEMENT, L.P. removed 1,539,860 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $14,336,096
- FEDERATED HERMES, INC. removed 1,209,844 shares (-84.5%) from their portfolio in Q2 2026, for an estimated $16,090,925
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 644,047 shares (+40.1%) to their portfolio in Q2 2026, for an estimated $8,565,825
- DIADEMA PARTNERS LP added 571,107 shares (+inf%) to their portfolio in Q2 2026, for an estimated $7,595,723
- ACUTA CAPITAL PARTNERS, LLC added 507,801 shares (+inf%) to their portfolio in Q2 2026, for an estimated $6,753,753
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$FDMT Price Targets
Multiple analysts have issued price targets for $FDMT recently. We have seen 4 analysts offer price targets for $FDMT in the last 6 months, with a median target of $30.5.
Here are some recent targets:
- Faisal Khurshid from Jefferies set a target price of $21.0 on 03/30/2026
- Matthew Caufield from HC Wainwright & Co. set a target price of $36.0 on 03/20/2026
- Lisa Walter from RBC Capital set a target price of $35.0 on 03/19/2026
- Geulah Livshits from Chardan Capital set a target price of $26.0 on 03/19/2026
Full Release
EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on September 8, 2026, the compensation committee of the Company’s board of directors granted seven new non-executive employees 96,000 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn .
